Listeria-based vaccination against the pericyte antigen RGS5 elicits anti-vascular effects and colon cancer protection

References

• Xi Y, Xu P. Global colorectal cancer burden in 2020 and projections to 2040. Transl Oncol. 2021;14(10):101174. doi:10.1016/j.tranon.2021.101174.
   PubMed Web of Science ®Google Scholar
• Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–14. doi:10.3322/caac.21660.
   PubMed Web of Science ®Google Scholar
• Turano M, Delrio P, Rega D, Cammarota F, Polverino A, Duraturo F, Izzo P, De Rosa M. Promising colorectal cancer biomarkers for precision prevention and therapy. Cancers Basel. 2019;11(12):1932. doi:10.3390/cancers11121932.
   PubMed Web of Science ®Google Scholar
• Van der Jeught K, Xu H-C, Li Y-J, Lu X-B, Ji G. Drug resistance and new therapies in colorectal cancer. World J Gastroenterol. 2018;24(34):3834–3848. doi:10.3748/wjg.v24.i34.3834.
   PubMed Web of Science ®Google Scholar
• Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 2000;355(9209):1041–1047. doi:10.1016/S0140-6736(00)02034-1.
   PubMed Web of Science ®Google Scholar
• Fan A, Wang B, Wang X, Nie Y, Fan D, Zhao X, Lu Y. Immunotherapy in colorectal cancer: current achievements and future perspective. Int J Biol Sci. 2021;17(14):3837–3849. doi:10.7150/ijbs.64077.
   PubMed Web of Science ®Google Scholar
• Jia W, Zhang T, Huang H, Feng H, Wang S, Guo Z, Luo Z, Ji X, Cheng X, Zhao R, et al. Colorectal cancer vaccines: the current scenario and future prospects. Front Immunol. 2022;13:942235. doi:10.3389/fimmu.2022.942235.
   PubMed Web of Science ®Google Scholar
• Berry J, Vreeland T, Trappey A, Hale D, Peace K, Tyler J, Walker A, Brown R, Herbert G, Yi F, et al. Cancer vaccines in colon and rectal cancer over the last decade: lessons learned and future directions. Expert Rev Clin Immunol. 2017;13(3):235–245. doi:10.1080/1744666X.2016.1226132.
   PubMed Web of Science ®Google Scholar
• Sanchez-Leon ML, Jiménez-Cortegana C, Cabrera G, Vermeulen EM, de la Cruz-Merino L, Sánchez-Margalet V. The effects of dendritic cell-based vaccines in the tumor microenvironment: impact on myeloid-derived suppressor cells. Front Immunol. 2022;13:1050484. doi:10.3389/fimmu.2022.1050484.
   PubMed Web of Science ®Google Scholar
• Jahangir A, Chandra D, Quispe-Tintaya W, Singh M, Selvanesan BC, Gravekamp C. Immunotherapy with Listeria reduces metastatic breast cancer in young and old mice through different mechanisms. Oncoimmunology. 2017;6(9):e1342025. doi:10.1080/2162402X.2017.1342025.
   PubMed Web of Science ®Google Scholar
• Oladejo M, Nguyen H-M, Seah H, Datta A, Wood LM. Tumoral CD105 promotes immunosuppression, metastasis, and angiogenesis in renal cell carcinoma. Cancer Immunol Immunother. 2023;72(6):1633–1646. doi:10.1007/s00262-022-03356-5.
   PubMed Web of Science ®Google Scholar
• Zhou S, Gravekamp C, Bermudes D, Liu K. Tumour-targeting bacteria engineered to fight cancer. Nat Rev Cancer. 2018;18(12):727–743. doi:10.1038/s41568-018-0070-z.
   PubMed Web of Science ®Google Scholar
• Oladejo M, Paterson Y, Wood LM. Clinical experience and recent advances in the development of Listeria-based tumor immunotherapies. Front Immunol. 2021;12:642316. doi:10.3389/fimmu.2021.642316.
   PubMed Web of Science ®Google Scholar
• Fabian KL, Storkus WJ. Immunotherapeutic targeting of tumor-associated blood vessels. Adv Exp Med Biol. 2017;1036:191–211.
   PubMed Web of Science ®Google Scholar
• Schaaf MB, Garg AD, Agostinis P. Defining the role of the tumor vasculature in antitumor immunity and immunotherapy. Cell Death Disease. 2018;9(2):115. doi:10.1038/s41419-017-0061-0.
   PubMed Web of Science ®Google Scholar
• Martin JD, Seano G, Jain RK. Normalizing function of tumor vessels: progress, opportunities, and challenges. Annu Rev Physiol. 2019;81(1):505–534. doi:10.1146/annurev-physiol-020518-114700.
   PubMedGoogle Scholar
• Garza Trevino EN, González PD, Valencia Salgado CI, Martinez Garza A. Effects of pericytes and colon cancer stem cells in the tumor microenvironment. Cancer Cell Int. 2019;19(1):173. doi:10.1186/s12935-019-0888-9.
   PubMedGoogle Scholar
• Berger M, Bergers G, Arnold B, Hammerling GJ, Ganss R. Regulator of G-protein signaling-5 induction in pericytes coincides with active vessel remodeling during neovascularization. Blood. 2005;105(3):1094–1101. doi:10.1182/blood-2004-06-2315.
   PubMed Web of Science ®Google Scholar
• Dabravolski SA, Andreeva ER, Eremin II, Markin AM, Nadelyaeva II, Orekhov AN, Melnichenko AA. The role of pericytes in regulation of innate and adaptive immunity. Biomedicines. 2023;11(2):600. doi:10.3390/biomedicines11020600.
   PubMed Web of Science ®Google Scholar
• Raza A, Franklin MJ, Dudek AZ. Pericytes and vessel maturation during tumor angiogenesis and metastasis. Am J Hematol. 2010;85(8):593–598. doi:10.1002/ajh.21745.
   PubMed Web of Science ®Google Scholar
• Zhao X, Bose A, Komita H, Taylor JL, Chi N, Lowe DB, Okada H, Cao Y, Mukhopadhyay D, Cohen PA, et al. Vaccines targeting tumor blood vessel antigens promote CD8(+) T cell-dependent tumor eradication or dormancy in HLA-A2 transgenic mice. J Immunol. 2012;188(4):1782–1788. doi:10.4049/jimmunol.1101644.
   PubMed Web of Science ®Google Scholar
• Hamzah J, Jugold M, Kiessling F, Rigby P, Manzur M, Marti HH, Rabie T, Kaden S, Gröne H-J, Hämmerling GJ, et al. Vascular normalization in Rgs5-deficient tumours promotes immune destruction. Nature. 2008;453(7193):410–414. doi:10.1038/nature06868.
   PubMed Web of Science ®Google Scholar
• Storkus WJ, Maurer D, Lin Y, Ding F, Bose A, Lowe D, Rose A, DeMark M, Karapetyan L, Taylor JL, et al. Dendritic cell vaccines targeting tumor blood vessel antigens in combination with dasatinib induce therapeutic immune responses in patients with checkpoint-refractory advanced melanoma. J Immunother Cancer. 2021;9(11):e003675. doi:10.1136/jitc-2021-003675.
   PubMed Web of Science ®Google Scholar
• Singh R, Dominiecki ME, Jaffee EM, Paterson Y. Fusion to listeriolysin O and delivery by Listeria monocytogenes enhances the immunogenicity of HER-2/neu and reveals subdominant epitopes in the FVB/N mouse. J Immunol. 2005;175(6):3663–3673. doi:10.4049/jimmunol.175.6.3663.
   PubMed Web of Science ®Google Scholar
• Kim SH, Castro F, Gonzalez D, Maciag PC, Paterson Y, Gravekamp C. Mage-b vaccine delivered by recombinant Listeria monocytogenes is highly effective against breast cancer metastases. Br J Cancer. 2008;99(5):741–749. doi:10.1038/sj.bjc.6604526.
   PubMed Web of Science ®Google Scholar
• Monk IR, Gahan CG, Hill C. Tools for functional postgenomic analysis of listeria monocytogenes. Appl Environ Microbiol. 2008;74(13):3921–3934. doi:10.1128/AEM.00314-08.
   PubMed Web of Science ®Google Scholar
• Jones GS, D’Orazio SEF. Listeria monocytogenes: cultivation and laboratory maintenance. Curr Protoc Microbiol. 2013;31(1):B9 2 1–B9 2 7. doi:10.1002/9780471729259.mc09b02s31.
   Google Scholar
• Son YI, Egawa S-I, Tatsumi T, Redlinger RE, Kalinski P, Kanto T. A novel bulk-culture method for generating mature dendritic cells from mouse bone marrow cells. J Immunol Methods. 2002;262(1–2):145–157. doi:10.1016/S0022-1759(02)00013-3.
   PubMed Web of Science ®Google Scholar
• Mailliard RB, Wankowicz-Kalinska A, Cai Q, Wesa A, Hilkens CM, Kapsenberg ML, Kirkwood JM, Storkus WJ, Kalinski P. α-type-1 polarized dendritic cells. Cancer Res. 2004;64(17):5934–5937. doi:10.1158/0008-5472.CAN-04-1261.
   PubMed Web of Science ®Google Scholar
• Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods. 2001;25(4):402–408. doi:10.1006/meth.2001.1262.
   PubMed Web of Science ®Google Scholar
• Andreatta M, Nielsen M. Gapped sequence alignment using artificial neural networks: application to the MHC class I system. Bioinformatics. 2016;32(4):511–517. doi:10.1093/bioinformatics/btv639.
   PubMed Web of Science ®Google Scholar
• Nielsen M, Lundegaard C, Worning P, Lauemøller SL, Lamberth K, Buus S, Brunak S, Lund O. Reliable prediction of T-cell epitopes using neural networks with novel sequence representations. Protein Sci. 2003;12(5):1007–1017. doi:10.1110/ps.0239403.
   PubMed Web of Science ®Google Scholar
• Lowe DB, Bose A, Taylor JL, Tawbi H, Lin Y, Kirkwood JM, Storkus WJ. Dasatinib promotes the expansion of a therapeutically superior T-cell repertoire in response to dendritic cell vaccination against melanoma. Oncoimmunology. 2014;3(2):e27589. doi:10.4161/onci.27589.
   PubMed Web of Science ®Google Scholar
• Liu Y, Niu L, Li N, Wang Y, Liu M, Su X, Bao X, Yin B, Shen S. Bacterial-mediated tumor therapy: old treatment in a New context. Adv Sci. 2023;10(12):e2205641. doi:10.1002/advs.202205641.
   Web of Science ®Google Scholar
• Wood LM, Pan Z-K, Guirnalda P, Tsai P, Seavey M, Paterson Y. Targeting tumor vasculature with novel Listeria-based vaccines directed against CD105. Cancer Immunol Immunother. 2011;60(7):931–942. doi:10.1007/s00262-011-1002-x.
   PubMed Web of Science ®Google Scholar
• Gunn GR, Zubair A, Peters C, Pan ZK, Wu TC, Paterson Y. Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16. J Immunol. 2001;167(11):6471–6479. doi:10.4049/jimmunol.167.11.6471.
   PubMed Web of Science ®Google Scholar
• Chandra D, Jahangir A, Quispe-Tintaya W, Einstein MH, Gravekamp C. Myeloid-derived suppressor cells have a central role in attenuated Listeria monocytogenes-based immunotherapy against metastatic breast cancer in young and old mice. Br J Cancer. 2013;108(11):2281–2290. doi:10.1038/bjc.2013.206.
   PubMed Web of Science ®Google Scholar
• Kheirolomoom A, Kare AJ, Ingham ES, Paulmurugan R, Robinson ER, Baikoghli M, Inayathullah M, Seo JW, Wang J, Fite BZ, et al. In situ T-cell transfection by anti-CD3-conjugated lipid nanoparticles leads to T-cell activation, migration, and phenotypic shift. Biomaterials. 2022;281:121339. doi:10.1016/j.biomaterials.2021.121339.
   PubMed Web of Science ®Google Scholar
• Ghanekar SA, Nomura LE, Suni MA, Picker LJ, Maecker HT, Maino VC. Gamma interferon expression in CD8+T cells is a marker for circulating cytotoxic T lymphocytes that recognize an HLA A2-restricted epitope of human cytomegalovirus phosphoprotein pp65. Clin Diagn Lab Immunol. 2001;8(3):628–631. doi:10.1128/CDLI.8.3.628-631.2001.
   PubMedGoogle Scholar
• Horton H, Russell N, Moore E, Frank I, Baydo R, Havenar‐Daughton C, Lee D, Deers M, Hudgens M, Weinhold K, et al. Correlation between Interferon-γ secretion and cytotoxicity, in Virus-specific Memory T cells. J Infect Dis. 2004;190(9):1692–1696. doi:10.1086/424490.
   PubMed Web of Science ®Google Scholar
• Simon S, Labarriere N. PD-1 expression on tumor-specific T cells: friend or foe for immunotherapy? Oncoimmunology. 2017;7(1):e1364828. doi:10.1080/2162402X.2017.1364828.
   PubMed Web of Science ®Google Scholar
• Montfort A, Colacios C, Levade T, Andrieu-Abadie N, Meyer N, Ségui B. The TNF paradox in cancer progression and immunotherapy. Front Immunol. 2019;10:1818. doi:10.3389/fimmu.2019.01818.
   PubMed Web of Science ®Google Scholar
• Oladejo M, Nguyen H-M, Silwal A, Reese B, Paulishak W, Markiewski MM, Wood LM. Listeria-based immunotherapy directed against CD105 exerts anti-angiogenic and anti-tumor efficacy in renal cell carcinoma. Front Immunol. 2022;13:1038807. doi:10.3389/fimmu.2022.1038807.
   PubMed Web of Science ®Google Scholar
• Lechner MG, Karimi SS, Barry-Holson K, Angell TE, Murphy KA, Church CH, Ohlfest JR, Hu P, Epstein AL. Immunogenicity of murine solid tumor models as a defining feature of in vivo behavior and response to immunotherapy. J Immunother (1991). 2013;36(9):477–489. doi:10.1097/01.cji.0000436722.46675.4a.
   Web of Science ®Google Scholar
• Lau J, Cheung J, Navarro A, Lianoglou S, Haley B, Totpal K, Sanders L, Koeppen H, Caplazi P, McBride J, et al. Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice. Nat Commun. 2017;8(1):14572. doi:10.1038/ncomms14572.
   PubMedGoogle Scholar
• Li HY, McSharry M, Bullock B, Nguyen TT, Kwak J, Poczobutt JM, Sippel TR, Heasley LE, Weiser-Evans MC, Clambey ET, et al. The tumor microenvironment regulates sensitivity of murine lung tumors to PD-1/PD-L1 antibody blockade. Cancer Immunol Res. 2017;5(9):767–777. doi:10.1158/2326-6066.CIR-16-0365.
   PubMed Web of Science ®Google Scholar
• Ganesh K, Stadler ZK, Cercek A, Mendelsohn RB, Shia J, Segal NH, Diaz LA. Immunotherapy in colorectal cancer: rationale, challenges and potential. Nat Rev Gastroenterol Hepatol. 2019;16(6):361–375. doi:10.1038/s41575-019-0126-x.
   PubMed Web of Science ®Google Scholar
• Goel S, Duda DG, Xu L, Munn LL, Boucher Y, Fukumura D, Jain RK. Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev. 2011;91(3):1071–1121. doi:10.1152/physrev.00038.2010.
   PubMed Web of Science ®Google Scholar
• Tian L, Goldstein A, Wang H, Ching Lo H, Sun Kim I, Welte T, Sheng K, Dobrolecki LE, Zhang X, Putluri N, et al. Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming. Nature. 2017;544(7649):250–254. doi:10.1038/nature21724.
   PubMed Web of Science ®Google Scholar
• Liu Z, Wang Y, Huang Y, Kim BYS, Shan H, Wu D, Jiang W. Tumor vasculatures: a New target for cancer immunotherapy. Trends Pharmacol Sci. 2019;40(9):613–623. doi:10.1016/j.tips.2019.07.001.
   PubMed Web of Science ®Google Scholar
• Yang S, Fei W, Zhao Y, Wang F, Ye Y, Wang F. Combat against gynecological cancers with blood vessels as entry point: Anti-angiogenic drugs, clinical trials and pre-clinical nano-delivery platforms. Int J Nanomedicine. 2023;18:3035–3046. doi:10.2147/IJN.S411761.
   PubMed Web of Science ®Google Scholar
• Baar J, Storkus WJ, Finke J, Butterfield L, Lazarus H, Reese J, Downes K, Budd T, Brufsky A, Fu P. Pilot trial of a type I - polarized autologous dendritic cell vaccine incorporating tumor blood vessel antigen-derived peptides in patients with metastatic breast cancer. J Immunother Cancer. 2015;33(S1):P3. doi:10.1186/2051-1426-3-S1-P3.
   PubMedGoogle Scholar
• Stapor PC, Sweat RS, Dashti DC, Betancourt AM, Murfee WL. Pericyte dynamics during angiogenesis: new insights from new identities. J Vasc Res. 2014;51(3):163–174. doi:10.1159/000362276.
   PubMed Web of Science ®Google Scholar
• Meng MB, Zaorsky NG, Deng L, Wang H-H, Chao J, Zhao L-J, Yuan Z-Y, Ping W. Pericytes: a double-edged sword in cancer therapy. Future Oncol. 2015;11(1):169–179. doi:10.2217/fon.14.123.
   PubMed Web of Science ®Google Scholar
• Firat H, Garcia-Pons F, Tourdot S, Pascolo S, Scardino A, Garcia Z, Michel M-L, Jack RW, Jung G, Kosmatopoulos K, et al. H-2 class I knockout, HLA-A2.1-transgenic mice: a versatile animal model for preclinical evaluation of antitumor immunotherapeutic strategies. Eur J Immunol. 1999;29(10):3112–3121. doi:10.1002/(SICI)1521-4141(199910)29:10<3112:AID-IMMU3112>3.0.CO;2-Q.
   PubMed Web of Science ®Google Scholar
• Street MD, Doan T, Herd KA, Tindle RW. Limitations of HLA-transgenic mice in presentation of HLA-restricted cytotoxic T-cell epitopes from endogenously processed human papillomavirus type 16 E7 protein. Immunology. 2002;106(4):526–536. doi:10.1046/j.1365-2567.2002.01442.x.
   PubMed Web of Science ®Google Scholar
• Angelakopoulos H, Loock K, Sisul DM, Jensen ER, Miller JF, Hohmann EL. Safety and shedding of an attenuated strain of Listeria monocytogenes with a deletion of actA/plcb in adult volunteers: a dose escalation study of oral inoculation. Infect Immun. 2002;70(7):3592–3601. doi:10.1128/IAI.70.7.3592-3601.2002.
   PubMed Web of Science ®Google Scholar
• Maciag PC, Radulovic S, Rothman J. The first clinical use of a live-attenuated Listeria monocytogenes vaccine: a phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix. Vaccine. 2009;27(30):3975–3983. doi:10.1016/j.vaccine.2009.04.041.
   PubMed Web of Science ®Google Scholar
• Tsujikawa T, Crocenzi T, Durham JN, Sugar EA, Wu AA, Onners B, Nauroth JM, Anders RA, Fertig EJ, Laheru DA, et al. Evaluation of cyclophosphamide/GVAX pancreas followed by Listeria-mesothelin (CRS-207) with or without nivolumab in patients with pancreatic cancer. Clin Cancer Res. 2020;26(14):3578–3588. doi:10.1158/1078-0432.CCR-19-3978.
   PubMed Web of Science ®Google Scholar
• Mason NJ, Gnanandarajah JS, Engiles JB, Gray F, Laughlin D, Gaurnier-Hausser A, Wallecha A, Huebner M, Paterson Y. Immunotherapy with a HER2-targeting Listeria induces HER2-specific immunity and demonstrates potential therapeutic effects in a phase I trial in canine osteosarcoma. Clin Cancer Res. 2016;22(17):4380–4390. doi:10.1158/1078-0432.CCR-16-0088.
   PubMed Web of Science ®Google Scholar
• Wallecha A, Malinina I, Molli P. Listeria monocytogenes (Lm)-LLO immunotherapies reduce the immunosuppressive activity of myeloid-derived suppressor cells and regulatory T cells in the tumor microenvironment. J Immunother Cancer. 2013;1(S1):468–476. doi:10.1186/2051-1426-1-S1-O18.
   Google Scholar